PTCB Guide to Cholesterol-lowering Drugs.

At a Glance.

According to Johns Hopkins University, over 70 million people in the United States have elevated cholesterol levels. Prolonged high cholesterol levels predispose patients to serious cardiovascular risks, including heart attacks and strokes.

And two-thirds of these patients take some form of cholesterol-lowering agent – though statins are by far the most common. Given the prevalence of hypercholesterolemia and the prescribing and dispensing of cholesterol-lowering agents, this topic is highly relevant and is therefore always tested on the PTCB exam in some form.

For the PTCB exam, pharmacy technicians should focus on:

• Recognizing the major cholesterol-lowering drug classes.
• Identifying the most common examples of each class.
• Major side effects and adverse reactions.
• Key food-drug and drug-drug interactions.
• Brand names.

Cholesterol lowering agents include drugs such as statins, ezetimibe, fibrates, bile acid sequestrants, and newer agents such as PCSK9 inhibitors. Pharmacy technicians should be able to identify medications within each class, understand their broad mechanism of action, and to recognize key safety concerns. For example, statins are associated with muscle pain and elevated liver enzymes, whereas fibrates can increase the risk of gallstones and muscle-related adverse effects.

It is also helpful to know a basic, high-level description of how each class works, such as statins reducing cholesterol production or ezetimibe decreasing cholesterol absorption. However, detailed mechanisms of action are not a major focus.

Pharmacy technicians are not required to memorize cholesterol treatment guidelines, LDL reduction percentages, cardiovascular outcomes data, complex prescribing decisions, or counseling points. The emphasis should remain on drug identification, common adverse effects, interactions, and essential medication safety concepts.

The following table covers core details that technicians should know – including class, examples, broad mechanism of action, and notable adverse effects:

Class	Mechanism	Adverse Effects
Statins Atorvastatin Rosuvastatin Simvastatin Pravastatin Lovastatin	Inhibit the HMG-CoA reductase enzyme – a key enzyme in the mevalonate pathway of cholesterol production by the liver.	Myopathy Rhabdomyolysis Elevated liver enzymes
Cholesterol absorption inhibitor Ezetimibe	Ezetimibe works by blocking the absorption of cholesterol from the small intestine, which reduces the amount of cholesterol entering the bloodstream. Specifically, it blocks NPC1L1-mediated cholesterol absorption.	Diarrhea Elevated liver enzymes (when combined with statins)
Bile acid sequestrants Cholestyramine Colestipol Colesevelam	Bind bile acids in the gut, increasing conversion of cholesterol to bile acids.	Constipation Bloating
Fibrates Fenofibrate Gemfibrozil	Fibrates activate PPAR-α receptors, increasing the breakdown and removal of triglycerides from the bloodstream, which lowers triglyceride levels.	Gallstones Myopathy Elevated liver enzymes
PCSK9 Inhibitors Alirocumab Evolocumab	PCSK9 inhibitors block the PCSK9 protein, allowing the liver to remove more LDL (“bad”) cholesterol from the bloodstream and thereby lower LDL levels.	Injection-site reactions
siRNA PCSK9 Inhibitor Inclisiran	Silences hepatic PCSK9 production.	Injection-site reactions
ATP citrate lyase inhibitor Bempedoic acid	Inhibits cholesterol synthesis upstream of HMG-CoA reductase.	Hyperuricemia Tendon rupture (rare)
Niacin	Decreases hepatic VLDL synthesis.	Flushing Hyperglycemia Hyperuricemia

Key Clinical Factors in Review.

Recall that technicians are not required to learn detailed mechanisms of action, and that all medicines discussed are used to treat hypercholesterolemia.

With indications and mechanism of action now covered, we can focus on the key clinical features that distinguish one drug class from another. This approach helps streamline your studying by concentrating on the relevant differences – such as adverse effects, interactions, and key clinical factors – that are most useful for differentiating between classes.

• Statins are considered first-line agents in the treatment of hypercholesterolemia. In other words, due to their relative effectiveness, these drugs are the preferred first drugs used to manage the condition.
• Grapefruit juice interacts with some statins, though not all statins. Grapefruit juice should be avoided with Simvastatin, Lovastatin, and Atorvastatin.
• Think ‘SLAM’ drugs to help remember all three, where M stands for Metabolized by CYP 3A4, therefore grapefruit juice interaction. This food-drug interaction increases the risk of adverse effects, particularly muscle-related effects such as myopathies.
• Statins are teratogenic and so should be avoided in pregnancy. This is because cholesterol is essential for normal fetal development. For similar reasons, statins must be avoided in women who are breastfeeding.
• Most statins are recommended to be taken at night because that’s when cholesterol production is at its highest.

For most patients with hypercholesterolemia, statins are effective at reducing harmful LDL cholesterol and increasing beneficial HDL cholesterol. In treatment-resistant cases, additional drugs may be required – what are referred to as second line and third line agents:

• Ezetimibe – often the first add-on to a statin or an alternative for statin intolerance.
• Alirocumab / evolocumab – injectable PCSK9 inhibitors used for patients requiring substantial additional LDL reduction.
• Inclisiran – a newer injectable therapy that reduces PCSK9 production.
• Bempedoic acid – an oral option, particularly useful in patients who cannot tolerate statins.
• Cholestyramine, colestipol, and colesevelam – older alternatives that may be used in selected patients.

We haven’t yet mentioned fibrates, and that’s because fibrates are primarily used for elevated triglycerides rather than as second-line LDL-lowering agents.

Cholesterol, Triglycerides, and Fibrates.

Cholesterol and triglycerides are both lipids found in the blood; a type of fat. But they serve different purposes:

• Cholesterol is used to build cell membranes and produce hormones, vitamin D, and bile acids.
• Triglycerides are the body’s main form of stored energy and are used as a fuel source between meals.

When cholesterol levels, particularly LDL cholesterol, are elevated, treatment usually focuses on statins and other LDL-lowering drugs. In contrast, fibrates such as fenofibrate and gemfibrozil are primarily used when triglyceride levels are significantly elevated, especially when there is concern about complications such as acute pancreatitis.

Fibrates activate PPAR-α, increasing the breakdown and clearance of triglyceride-rich lipoproteins, making them much more effective at lowering triglycerides than at lowering LDL cholesterol.

A useful rule of thumb is: statins are mainly for high cholesterol, whereas fibrates are mainly for high triglycerides. Other drugs may be used as add-on therapies in cases where both cholesterol and triglycerides levels are too high.

Interestingly, fibrates and statins share two adverse effects: myopathies and elevated liver enzymes. Therefore, in cases where patients are prescribed both a statin and a fibrate, the risk of myopathies and elevated liver enzyme is even higher.

Note also that fibrates can cause gallstones (cholelithiasis).

Notable Brand Names.

Pharmacy technicians are required to know major brand names of cholesterol-lowering agents.

Though brand names are tested, questions on this topic are likely to be asked on statins, fibrates, ezetimibe, and PCSK9 inhibitors.

From our experience, brand names for bempedoic acid and inclisiran are unlikely to be tested. However, for completeness, the table below summarizes the brand names of all drugs covered in this study guide:

Drug	Brand names
Atorvastatin Simvastatin Lovastatin Rosuvastatin Fluvastatin Pravastatin	Lipitor Zocor Altoprev Crestor Lescol XL Generic versions available
Ezetimibe	Zetia
Alirocumab Evolocumab	Praluent Repatha
Fenofibrate Gemfibrozil Clofibrate	TriCor Lopid Atromid
Colestipol Cholestyramine Colesevelam	Colestid Prevalite Welchol
Bempedoic acid	Nexletol
Inclisiran	Leqvio

Sample PTCB Exam Questions.

Below, we put together five PTCB exam-style questions on the topic of cholesterol-lowering agents.

These questions reflect the standard and difficulty of questions tested about cholesterol-lowering drugs on the pharmacy technician exam. Take a moment to first answer each question before learning more about each answer explanations in the section below.

Question 1.

A patient presents in the local pharmacy with a valid 6-month prescription for TriCor. Identify the active ingredient of this medicine:

a. Simvastatin

b. Ezetimibe

c. Fenofibrate

d. Cholestyramine

Question 2.

Grapefruit juice should be avoided with all the following statins, except?

a. Atorvastatin

b. Simvastatin

c. Lovastatin

d. Rosuvastatin

Question 3.

Identify the PCSK9 inhibitor from the following list of medications:

a. Evolocumab

b. Bempedoic acid

c. Niacin

d. Clofibrate

Question 4.

A patient comes to the pharmacy reporting significant muscle pain and weakness. After reviewing their medication profile, which of the following drugs is most likely responsible for these symptoms?

a. Isosorbide mononitrate

b. Niacin

c. Bisoprolol

d. Atorvastatin

Question 5.

Which of these drugs binds bile acids in the gut, increasing conversion of cholesterol to bile acids?

a. Ezetimibe

b. Bempedoic acid

c. Cholestyramine

d. Gemfibrozil

Answer Explanations.

Answer to Question 1 – c. Fenofibrate

Fenofibrate is the active ingredient of the medicine, TriCor. This medicine is used to lower triglyceride levels in patients with elevated triglyceride levels, or hypertriglyceridemia.

Answer to Question 2 – d. Rosuvastatin

Rosuvastatin is not broken down by the same liver enzyme that grapefruit blocks. Grapefruit juice should be avoided with the SLAM drugs – Simvastatin, Lovastatin, and Atorvastatin; as all three are Metabolized by CYP 3A4.

Answer to Question 3 – a. Evolocumab

Evolocumab, as well as alirocumab, are PCSK9 inhibitors that block the PCSK9 protein, allowing the liver to remove more LDL (“bad”) cholesterol from the bloodstream and thereby lower LDL levels. Unlike many other cholesterol-lowering agents, these drugs are injectable agents.

Answer to Question 4 – d. Atorvastatin

Statins, particularly at high doses for prolonged periods, are associated with myopathies that can cause muscle weakness and pain. This risk is heightened if the patient is also taking a fibrate.

Answer to Question 5 – c. Cholestyramine

Bile acid sequestrants work by binding bile acids in the gut, increasing conversion of cholesterol to bile acids. This lowers blood cholesterol levels over time. Examples include cholestyramine, colestipol, and colesevelam.

PTCB Cheat Sheet on Cholesterol-lowering Agents.

Statins (first-line agents)

Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Pravastatin
MOA: inhibit HMG-CoA reductase → ↓ cholesterol synthesis in liver
Key AEs: muscle pain (myopathy), rhabdomyolysis (rare), ↑ liver enzymes
Key Interactions:

• Grapefruit juice (SLAM: Simvastatin, Lovastatin, Atorvastatin)
• Elevated myopathy risk with fibrates (higher with gemfibrozil)
• Most statins are taken at night when cholesterol production is highest
• Statins are teratogenic – avoid in pregnancy + breastfeeding

Ezetimibe (absorption blocker)
MOA: blocks NPC1L1 in intestine → ↓ cholesterol absorption
Key AEs: GI upset, mild increase in liver enzymes – higher when combined with statins

Bile Acid Sequestrants

Cholestyramine, Colestipol, Colesevelam
MOA: bind bile acids in gut → liver uses cholesterol to make more bile acids
Key AEs: constipation, bloating, reduces absorption of other drugs

Fibrates (triglycerides)

Fenofibrate, Gemfibrozil, Clofibrate
MOA: Activate PPAR-α → ↑ lipoprotein lipase → ↓ triglycerides
Key AEs: gallstones, myopathy, ↑ creatinine
Key Interaction: high risk of muscle toxicity with statins (esp. gemfibrozil)

PCSK9 Inhibitors (very strong LDL lowering)

Alirocumab, Evolocumab
MOA: Prevent LDL receptor breakdown → ↑ LDL clearance
Key AEs: injection site reactions

Other / Newer Agents

Bempedoic Acid
MOA: blocks cholesterol synthesis upstream of statins
AEs: hyperuricemia, tendon rupture (rare)

Inclisiran
MOA: siRNA → ↓ PCSK9 production in liver
AEs: Injection site reactions

Key Clinical Factors

• Statins = muscle pain risk
• Ezetimibe = blocks absorption
• Resins = bind bile acids → constipation + drug interactions
• Fibrates = triglycerides + gallstones + muscle risk
• PCSK9 = injectable LDL super-lowering drugs
• Biggest interaction = statins + gemfibrozil → myopathy/rhabdo risk

That concludes our PTCB review of cholesterol-lowering agents – all the essential, key details that get tested!

We hope that you found this guide helpful. For more exclusive content and course materials to help you ace the PTCB exam on your first attempt, consider becoming a full member of our online program.